Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,734 calls trading, 1.3x expected, and implied vol increasing almost 4 points ...

Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...

Financial disclosures released ahead of confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the health ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. Meanwhile ...

CRISPR Therapeutics has a 12-month low of $36.52 and a 12-month high of $91.10. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings results on Tuesday ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...

CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR ...

View CRISPR Therapeutics AG (CRSP) current and estimated P/E ratio data provided by Seeking Alpha.

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.